Scilex Holding Company announced that it has filed a New Drug Submission (NDS) to Health Canada?s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | +3.45% | +20.74% | -55.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.88% | 109M | |
+10.74% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.83% | 2.3B | |
-29.65% | 2.21B | |
+19.51% | 2.17B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada